Pfizer, Inc. (PFE) Earnings Call Analysis

NYSE · Healthcare · Drug Manufacturers - General

23/25

Growth 5 Margin 5 Expansion 5 Platform 3 Financial 5

latest quarter score

Earnings Reports

23
Pfizer (PFE) Q2 2026: Cost Savings Climb to $9.7B, Powering Post-2028 Growth Strategy
August 04, 2026
24
Pfizer (PFE) Q1 2026: New Products Drive 22% Growth, Post-2028 Revenue Trajectory Strengthens
May 05, 2026
16
Pfizer (PFE) Q4 2025: Non-COVID Portfolio Grows 9% as Obesity Pipeline Targets $150B Market
February 03, 2026
11
Pfizer (PFE) 2026 Guidance: $17B LOE Headwind Drives Margin Compression, Obesity Pipeline Anchors Post-2028 Growth
December 17, 2025
19
Pfizer (PFE) Q3 2025: Non-COVID Products Grow 4% as $7.7B Cost Savings Target Drives Margin Strength
November 04, 2025
20
Pfizer (PFE) Q2 2025: New Launches Drive $4.7B, Margin Expansion Signals Post-LOE Resilience
August 05, 2025
20
Pfizer (PFE) Q2 2025: New Products Deliver $4.7B, Margin Expansion Accelerates Pipeline Bets
August 05, 2025
19
Pfizer (PFE) Q1 2025: $7.7B Cost Savings Target Sharpens Margin Focus Amid Tariff Uncertainty
July 01, 2025

Browse all companies